Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines

The introduction of pneumococcal vaccines into national immunization programmes around the world has reduced the incidence of pneumococcal vaccine serotypes, but had no influence on the incidence of Streptococcus pneumoniae serotype 3 included in their composition. The results of evaluation of epide...

Full description

Bibliographic Details
Published in:	Журнал микробиологии, эпидемиологии и иммунобиологии
Main Authors:	A. E. Zaitsev, E. A. Kurbatova, N. B. Egorova, E. V. Sukhova, N. E. Nifantiev
Format:	Article
Language:	Russian
Published:	Central Research Institute for Epidemiology 2020-04-01
Subjects:	streptococcus pneumoniae serotype 3 capsular pneumococcal polysaccharide conjugated pneumococcal vaccine polysaccharide pneumococcal vaccine epidemiological efficacy of pneumococcal vaccines opsonophagocytosis post-vaccination pneumococcal antibodies
Online Access:	https://microbiol.elpub.ru/jour/article/view/531

Similar Items

Global distribution and characteristics of pneumococcal serotypes in adults
by: Haruka Maeda, et al.
Published: (2025-12-01)

Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis
by: Kaile Chen, et al.
Published: (2018-06-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Epidemiology of Streptococcus pneumoniae serotypes in children before and after pneumococcal vaccination
by: I. N. Protasova, et al.
Published: (2021-12-01)

Vaccination against pneumococcal infections in adults
by: Kozlov R.S., et al.
Published: (2018-02-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

Efficacy of pneumococcal vaccine in immunocompetent and immunocompromised patients
by: M. P. Kostinov, et al.
Published: (2019-11-01)

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
by: Angel Vila-Córcoles, et al.
Published: (2023-04-01)

Emerging pneumococcal serotypes in Iraq: scope for improved vaccine development [version 2; peer review: 2 approved]
by: Ahmed H. Radhi, et al.
Published: (2023-12-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression
by: I. A. Guchev
Published: (2020-05-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world
by: Yadong A. Cui, et al.
Published: (2017-06-01)

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>
by: Thomas Chandler, et al.
Published: (2022-03-01)

Changes in Invasive Pneumococcal Disease Caused by <em>Streptococcus pneumoniae</em> Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
by: Julia C. Bennett, et al.
Published: (2021-03-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
by: Salil Bendre, et al.
Published: (2024-02-01)

Changes in invasive pneumococcal disease serotypes in a regional area of Australia following three years of 7vPCV introduction
by: Fakhrul Islam, et al.
Published: (2012-06-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

Systematic review on serotypes distribution of pneumococcal pneumonia in adults and the elderly
by: Fatiha Mrabt, et al.
Published: (2025-03-01)

The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects
by: Ioanna Papadatou, et al.
Published: (2019-01-01)

Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs
by: Johnna Perdrizet, et al.
Published: (2024-12-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

Increased Invasive Pneumococcal Disease, North East England, UK
by: Catherine Houseman, et al.
Published: (2017-01-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Chronic medical conditions associated with invasive pneumococcal diseases in inpatients in teaching hospitals in São Paulo city: Estimating antimicrobial susceptibility and serotype-coverage of pneumococcal vaccines
by: Renato A. Kfouri, et al.
Published: (2023-03-01)

Serotype Distribution and Antimicrobial Susceptibility Pattern of <i>Streptococcus pneumoniae</i> in COVID-19 Pandemic Era in Brazil
by: Samanta C. G. Almeida, et al.
Published: (2024-02-01)

Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
by: Xiuyan Li, et al.
Published: (2023-03-01)

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines
by: Qian-qian Du, et al.
Published: (2021-12-01)

Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024
by: Tzou-Yien Lin, et al.
Published: (2024-12-01)

Pneumococcal vaccine hyporesponsiveness in people living with HIV: A narrative review of immunological mechanisms and insights from minimally invasive lymph node sampling
by: Giovanni E. Loe-Sack-Sioe, et al.
Published: (2025-12-01)

Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
by: Juan Buades, et al.
Published: (2021-01-01)

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
by: Maria Deloria Knoll, et al.
Published: (2021-04-01)

An adult case of invasive pneumococcal disease due to serotype 12F-specific polysaccharide antibody failure following a 23-valent polysaccharide vaccination
by: Yasuhiro Tanaka, et al.
Published: (2020-01-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan
by: Katsunori Yanagihara, et al.
Published: (2021-01-01)

Pneumococcal Vaccine Uptake in Adults Before and After Hospitalization for Pneumococcal Infections in Hong Kong, 2015 to 2024
by: King-Pui Florence Chan, et al.
Published: (2025-05-01)

Individual protection and population effect – two sides of one medal
by: G. L. Ignatova, et al.
Published: (2018-10-01)